Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Large Decline in Short Interest

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling 17,840 shares, a drop of 35.0% from the December 15th total of 27,450 shares. Based on an average daily volume of 25,515 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.0% of the shares of the stock are sold short. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 25,515 shares, the days-to-cover ratio is currently 0.7 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC bought a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 2,979 shares of the company’s stock, valued at approximately $32,000. 0.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PHAR has been the subject of a number of recent research reports. Wall Street Zen raised Pharming Group to a “strong-buy” rating in a research note on Saturday, December 27th. Zacks Research lowered shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pharming Group in a research note on Monday, December 22nd. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $38.00.

Pharming Group Trading Up 1.5%

Shares of PHAR traded up $0.28 during midday trading on Friday, hitting $18.44. 17,891 shares of the stock were exchanged, compared to its average volume of 24,799. Pharming Group has a 52-week low of $7.50 and a 52-week high of $19.05. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.39 and a current ratio of 3.16. The stock has a fifty day simple moving average of $17.18 and a 200 day simple moving average of $14.41. The firm has a market cap of $1.26 billion and a P/E ratio of -1,842.16.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.05. Pharming Group had a return on equity of 0.46% and a net margin of 0.30%.The firm had revenue of $97.30 million for the quarter, compared to the consensus estimate of $98.22 million. On average, research analysts anticipate that Pharming Group will post -0.2 EPS for the current fiscal year.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.